Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction

Anna Walaszczyk1 | Emily Dookun1 | Rachael Redgrave1 | Simon Tual-Chalot1 | Stella Victorelli2,3 | Ioakim Spyridopoulos1 | Andrew Owens1 | Helen M. Arthur1 | João F. Passos2,3 | Gavin D. Richardson1

Cardiovascular disease (CVD) is a prevalent disease in the older population. The incidence of atherosclerotic coronary artery disease (CAD) increases with age and is present in over 50% of people over 60 years old (North & Sinclair, 2012). As such, older patients have a higher incidence of MI, which is accompanied by increased morbidity and mortality (Mehta et al., 2001).

Cellular senescence is classically defined as the irreversible cell cycle arrest of somatic cells. While senescence can act as a potent antitumour mechanism, recent studies have shown that senescent cells accumulate in several tissues with age where they contribute to age-related pathologies (de Magalhaes & Passos, 2018; Kirkland & Tchkonia, 2017). Senescent cells are thought to contribute to aging via a pro-oxidant phenotype (Passos et al., 2010) and the secretion of a senescence-associated...
secretory phenotype (SASP) (Coppe et al., 2008), which is pro-inflammatory, profibrotic and can also promote senescence in surrounding cells (Nelson et al., 2012). Senescence has been shown to occur in the heart during aging (Anderson et al., 2019) and contributes to the pathophysiology of a number of CVDs, as clearance of senescent cells in aged and atherosclerotic mice using both genetic and pharmacological approaches improves vascular and myocardial function and attenuates age-dependent remodelling (Anderson et al., 2019; Roos et al., 2016; Zhu et al., 2015). However, the impact of senescent cells in MI has not been investigated thus far. In this study, we hypothesise that senescent cells contribute to the poor prognosis and survival of aged individuals following MI.

FIGURE 1 Aged mice display increased CM senescence, CM hypertrophy, increased TGFβ2 expression and functional characteristics of myocardial aging, which are attenuated by navitoclax treatment. (a) Experimental design. (b) Percentage p16 + CMs by RNA in situ hybridization. Arrow indicates p16 expressing CMs (p16 red, troponin-C green, DAPI blue), n = 8 per group. Scale bars = 50 µm. (c) WGA staining and quantification of CM cross-sectional area, n = 6–10 per group. (d) TGFβ2 protein expression, n = 4–5 per group. (e) Examples of individual short axis cine-MR images. Analysis of (f) left ventricular mass and (g) ejection fraction. (h) % change in wall thickness, n = 14–34 per group. For c and d, scale bars = 100 µm. Data are mean ± SEM, ***p < 0.001; **p < 0.01; *p < 0.05 using Student’s t test or one-way ANOVA

FIGURE 2 Navitoclax treatment improves survival and functional outcome following MI. (a) Kaplan–Meier survival curve following MI, n = 20–45 per group. Dotted line indicates survival between the age of 104–109 weeks in a cohort of vehicle-treated mice that received no MI (n = 9). (b) Examples of individual short axis cine-MR images post-MI. ED = end diastole, ES = end systole. (c) Ejection fraction at 1 and 4 weeks post-MI, n = 9–15 per group. (d) Relative change in ejection fraction between 1 and 4 weeks post-MI, n = 7–11 per group. Data are mean ± SEM, ***p < 0.001; **p < 0.01; *p < 0.05 using one-way ANOVA
Previously we found that in addition to clearing senescent cells, navitoclax treatment reduced fibrosis and cardiomyocyte (CM) hypertrophy in aged mice (Anderson et al., 2019) and considered that these beneficial effects may help to improve outcomes in aged mice following MI. We therefore performed a more detailed longitudinal study to examine this possibility and to explore potential mechanisms (detailed methods are included in Appendix S1).

Histological analysis was performed on a cohort of noninfarcted mice, to assess the baseline effects of navitoclax treatment (50 mg kg\(^{-1}\) day\(^{-1}\) in the regime shown in Figure 1a). In addition to decreasing CM hypertrophy, treatment reduced markers of CM senescence, indicating clearance of senescent cells from the hearts of treated aged mice (Figure 1b–c). Furthermore, we found a significant reduction in expression of profibrotic TGFβ2 (Figure 1d), which we previously identified as a key component of CM SASP (Anderson et al., 2019). Functionally, navitoclax treatment significantly reduced the age-dependent increase in left ventricular (LV) mass (Figure 1f) but did not impact on clax treatment significantly reduced the age‐dependent increase from the hearts of treated aged mice (Figure 1b–c). Furthermore, weers of CM senescence, indicating clearance of senescent cells addition to decreasing CM hypertrophy, treatment reduced mark ‐ponent of CM SASP (Anderson et al., 2019). Functionally, navitoclax treatment significantly reduced the age‐dependent increase in left ventricular (LV) mass (Figure 1f) but did not impact on ejection fraction (EF) (Figure 1g). Aged mice also exhibited a decrease in the percentage change in diastole versus end systole LV wall thickness, indicating an increased LV rigidity compared with young animals, which was also partly rescued by navitoclax treatment (Figure 1h). Clinically, increased ventricle stiffness is related to fibrosis and hypertrophy during aging, is symptomatic of diastolic dysfunction and is observed in heart failure with preserved ejection fraction patients (Borlaug, 2014).

To investigate whether treatment with navitoclax improved outcome following MI, mice from each group were then subjected to ligation of the left anterior descending coronary artery (LAD), which mimics the pathophysiology of MI (Redgrave et al., 2017).

We observed that aged mice had significantly higher mortality rates following MI (60% over 5 weeks) compared with young mice and that this outcome was rescued by prior navitoclax treatment (Figure 2a). This high mortality also contrasts with the low mortality observed in a cohort of aged mice that received no MI (Figure 2a) and our previously published data that demonstrated a low mortality in male C57BL/6 mice between the same ages of 104–109 weeks (Jurk et al., 2014). Together these data suggest that reduced survival in old mice following LAD-igation was a result of the MI and was not due to aging alone. No difference in EF was observed between the MI groups at 1 week. However, in contrast to young mice, old mice show a significant reduction in EF between 1 and 4 weeks post-MI. Importantly, navitoclax was able to rescue this functional decline (Figure 2b–d) which may help to explain the improved survival of this group. Furthermore, expression of senescence markers p16 and p21 at 4 weeks following MI was reduced in the hearts of navitoclax-treated mice, consistent with reduction of the senescence burden (supporting information Figure S1A).

Collectively, this study shows that pharmacological clearance of senescent cells in aging mice alleviates age‐dependent myocardial remodelling and attenuates expression of profibrotic mediators. Navitoclax improved the maintenance of cardiac function following MI, ultimately increasing survival. An important limitation of this study is that our experimental strategy was not able to distinguish which senescent cell types are responsible for this effect, and it is possible that clearance of senescent cells in non‐cardiac organs impact on survival following MI. We have focussed our attention on CMs in this study as our earlier findings showed that, in the heart, markers of senescence accumulate primarily in CMs during aging (Anderson et al., 2019). However, further stud‐ies using animal models where senescent cells can be cleared in a cell-type specific manner are required to formally show the con‐tribution of senescent CMs to cardiac recovery post-MI. As seno‐lytics have now moved into clinical trials in other fibrotic diseases (Justice et al., 2019), we propose that senolytics may help to re‐duce the morbidity and mortality associated with MI in the older population.

CONFLICT OF INTEREST

None Declared.

AUTHOR CONTRIBUTIONS

AW, ED, RR, SV and ST-C performed experiments. AO, HMA and IS contributed to supervision. GDR and JFP designed and supervised the study. GDR, JFP and HMA wrote the manuscript with contributions from all authors.

ORCID

Helen M. Arthur https://orcid.org/0000-0001-6522-1363
João F. Passos https://orcid.org/0000-0001-8765-1890
Gavin D. Richardson https://orcid.org/0000-0002-2310-9987

REFERENCES

Anderson, R., Lagnado, A., Maggiorani, D., Walaszczyk, A., Dookun, E., Chapman, J., ... Passos, J. F. (2019). Length‐independent telomere damage drives post‐mitotic cardiomyocyte senescence. EMBO Journal, 38(5), e100492. https://doi.org/10.15252/embj.2018100492
Borlaug, B. A. (2014). The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology, 11(9), 507–515. https://doi.org/10.1038/nrcardio.2014.83
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y. u., Muñoz, D. P., Goldstein, J., ... Campisi, J. (2008). Senescence‐associated secretory phenotypes reveal cell‐nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biology, 6(12), 2853–2868. https://doi.org/10.1371/journal.pbio.0060301
de Magalhaes, J. P., & Passos, I. F. (2018). Stress, cell senescence and organismal ageing. Mechanisms of Ageing and Development, 170, 2–9. https://doi.org/10.1016/j.mad.2017.07.001
Jurk, D., Wilson, C., Passos, J. F., Oakley, F., Correia-Melo, C., Greaves, L., ... von Zglinicki, T. (2014). Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nature Communications, 2, 4172. https://doi.org/10.1038/ncomms5172
Justice, J. N., Nambar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., ... Kirkland, J. L. (2019). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. *EBioMedicine*. https://doi.org/10.1016/j.ebiom.2018.12.052

Kirkland, J. L., & Tchkonia, T. (2017). Cellular senescence: A translational perspective. *Ebiomedicine*, 21, 21-28. https://doi.org/10.1016/j.ebiom.2017.04.013

Redgrave, R. E., Tual-Chalot, S., Davison, B. J., Singh, E., Hall, D., Amirrasouli, M., ... Arthur, H. M. (2017). Cardiosphere-Derived Cells Require Endoglin for Paracrine-Mediated Angiogenesis. *Stem cell reports*, 8(5), 1287–1298.

Mehta, R. H., Rathore, S. S., Radford, M. J., Wang, Y., Wang, Y., & Krumholz, H. M. (2001). Acute myocardial infarction in the elderly: Differences by age. *Journal of the American College of Cardiology*, 38(3), 736–741. https://doi.org/10.1016/S0735-1097(01)01432-2

Nelson, G., Wordsworth, J., Wang, C., Jurk, D., Lawless, C., Martin-Ruiz, C., & von Zglinicki, T. (2012). A senescent cell bystander effect: Senescence-induced senescence. *Aging Cell*, 11(2), 345–349. https://doi.org/10.1111/j.1474-9726.2012.00795.x

North, B. J., & Sinclair, D. A. (2012). The intersection between aging and cardiovascular disease. *Circulation Research*, 110(8), 1097-1108. https://doi.org/10.1161/CIRCRESAHA.111.246876

Passos, J. F., Nelson, G., Wang, C., Richter, T., Simillion, C., Proctor, C. J., ... von Zglinicki, T. (2010). Feedback between p21 and reactive oxygen production is necessary for cell senescence. *Molecular Systems Biology*, 6, 347. https://doi.org/10.1038/msb.2010.5

Roos, C. M., Zhang, B., Palmer, A. K., Ogrodnik, M. B., Pirtskhalava, T., Thalji, N. M., ... Miller, J. D. (2016). Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. *Aging Cell*, 15(5), 973–977. https://doi.org/10.1111/acel.12458

Zhu, Y. i., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., ... Kirkland, J. L. (2015). The Achilles’ heel of senescent cells: From transcriptome to senolytic drugs. *Aging Cell*, 14(4), 644–658. https://doi.org/10.1111/acel.12344

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Walaszczyk A, Dookun E, Redgrave R, et al. Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction. *Aging Cell*. 2019;18:e12945. [https://doi.org/10.1111/acel.12945](https://doi.org/10.1111/acel.12945)